Loading
A phase 1/2 trial of DC05F01 in ovarian cancer and small-cell lung cancer, run by Heronova Pharmaceuticals, now recruiting.
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06873555 by Heronova Pharmaceuticals, with 60 participants planned, started 2024-09-11 and due to reach its primary completion in 2027-12. Interventions recorded: DC05F01.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/